What is Tesamorelin?
Tesamorelin is a synthetic analogue of Growth Hormone-Releasing Hormone (GHRH) — the endogenous peptide that stimulates the pituitary gland to release growth hormone. As a 44-amino acid peptide modeled on the full native GHRH sequence, with a modification that extends its half-life, tesamorelin has been a key research tool for studying pulsatile GH release, IGF-1 production, and visceral fat metabolism.
What Tesamorelin Is
Tesamorelin is a synthetic analogue of GHRH, the hypothalamic peptide responsible for triggering pituitary growth hormone secretion. It mimics the full 44-amino acid sequence of human GHRH, with a structural modification that gives it greater resistance to enzymatic degradation and a longer half-life than native GHRH.
Because tesamorelin works upstream of growth hormone itself — at the level of the GHRH receptor on the pituitary — it stimulates the body's own GH-producing cells (somatotrophs) rather than introducing exogenous GH. This places it in a distinct research category from direct GH administration.
Mechanism of Action
Tesamorelin's research interest centers on its position in the GH/IGF-1 axis:
GHRH receptor binding: Tesamorelin binds to GHRH receptors on pituitary somatotroph cells, stimulating the synthesis and release of endogenous growth hormone in its natural pulsatile pattern — rather than the sustained elevation seen with exogenous GH administration.
Pulsatile GH release: Because tesamorelin acts on the pituitary's own release machinery, the resulting GH secretion follows the body's normal pulsatile rhythm. This preserves the feedback regulation of the hypothalamic-pituitary GH axis, a key distinction researchers use when comparing GHRH analogues to direct GH or GH secretagogue approaches.
IGF-1 production: The increase in pulsatile GH release in turn increases hepatic production of IGF-1 (insulin-like growth factor 1), which mediates many of the downstream metabolic effects studied in tesamorelin research.
Research Applications
Tesamorelin is among the most clinically referenced GHRH analogues, with published research — including studies in JAMA — focused on the following areas:
| Research Area | Focus | Notes |
|---|---|---|
| Visceral adipose tissue | Visceral fat reduction | Primary focus of published JAMA research |
| Lean mass preservation | Body composition | Studied alongside fat-mass changes |
| Lipid metabolism | Triglycerides & lipid profile research | Downstream of IGF-1 / GH pathway activation |
| GH axis pharmacology | Pulsatile secretion studies | Used as a reference GHRH analogue |
The breadth of GH-axis-mediated effects makes tesamorelin a frequently referenced comparator compound in research on GHRH analogues and GH secretagogues more broadly.
Combination Research
Tesamorelin is sometimes studied alongside other research compounds to investigate cross-pathway effects:
With GLP-1 pathway compounds: Because tesamorelin's research focus (visceral fat, body composition via the GH/IGF-1 axis) and GLP-1/incretin pathway compounds (appetite, glucose metabolism) act through different mechanisms, researchers sometimes study the two together to characterize combined metabolic outcomes. Reconstitute each compound separately in its own vial — do not mix in the same vial.
With other GH-axis compounds: As a GHRH receptor agonist, tesamorelin is mechanistically distinct from GH secretagogue stacks such as CJC-1295 + Ipamorelin (which combine a GHRH analogue with a ghrelin-receptor agonist). Comparative research between the two approaches can help isolate the contribution of each receptor pathway. For more on the CJC-1295 + Ipamorelin mechanism, see our What is CJC-1295? guide.
Reconstitution for Research
Tesamorelin is supplied as a lyophilized (freeze-dried) powder and must be reconstituted with Bacteriostatic Water before use in research protocols.
Standard protocol for the 10mg vial: Add 2mL Bacteriostatic Water for a 5mg/mL concentration. The compound dissolves readily and produces a clear, colorless solution. Inject BAC Water slowly down the vial wall and swirl gently — do not shake. Refrigerate at 2-8°C after reconstitution. Stable 28-42 days.
For full reconstitution parameters and a dosing calculator that computes exact draw volumes, visit our Reconstitution Guide and Dosing Calculator.